Moderna and Merck reported this week that an experimental personalized mRNA-based vaccine demonstrated effectiveness in reducing the risk of melanoma coming back or spreading in a late-stage study of high-risk patients. According to the companies, the results could pave the way for a new treatment with the potential to prolong the lives of people diagnosed with this aggressive type of skin cancer.
Moderna and Merck announce success of experimental mRNA vaccine against melanoma recurrence
Moderna and Merck reported this week that an experimental personalized mRNA-based vaccine demonstrated effectiveness in reducing the risk of melanoma coming back or spreading in a late-stage study of high-risk patients. According to the...
The trial evaluated patients who underwent surgery to remove the tumor, with the aim of reducing the likelihood of recurrence after the operation. According to the companies, the study tested the personalized vaccine intismeran in combination with the immunotherapy Keytruda, one of Merck's main oncology drugs, and reached the main outcome of extending the...
- According to the companies, the study tested the personalized vaccine intismeran in combination with the immunotherapy Keytruda, one of Merck's main oncology drugs, and reached the main...
- The study also fulfilled a secondary objective by reducing the spread of the disease to other organs.
- The companies did not disclose specific data on progression-free survival time or median patient survival.
Editorial reading aid based only on information contained in this story and its identified source.
The trial evaluated patients who underwent surgery to remove the tumor, with the aim of reducing the likelihood of recurrence after the operation.
According to the companies, the study tested the personalized vaccine intismeran in combination with the immunotherapy Keytruda, one of Merck's main oncology drugs, and reached the main outcome of extending the time until cancer returns. The study also fulfilled a secondary objective by reducing the spread of the disease to other organs.
The companies did not disclose specific data on progression-free survival time or median patient survival. More details should be presented at a medical congress later this year.
Doctor warns of skin cancer symptom that is often ignored
Experts warn that the disease does not always appear as a dark spot. Wounds that do not heal, red spots and persistent lesions on the skin can be important signs and should not be ignored.